Pro-Inflammatory Effects of Colchicine on Macrophages Stimulated with Atherogenic Stimuli in Vitro

Schwarz, Nisha; Toledo-Flores, Deborah; Fernando, S.; Bartolo, Belinda A. Di

doi:10.1016/j.hlc.2016.06.210

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study carried out with mouse monocytes and macrophages revealed that colchicine could prevent monocyte proliferation and differentiation [43]. The authors found that the level of pro-inflammatory M1 macrophages is up-regulated, while that of anti-inflammatory M2 macrophages is down-regulated in the presence of colchicine [43].…”

Section: Responses Of Monocytes and Macrophages To Microtubule Inhmentioning

confidence: 99%

“…The authors found that the level of pro-inflammatory M1 macrophages is up-regulated, while that of anti-inflammatory M2 macrophages is down-regulated in the presence of colchicine [43]. These data demonstrate that colchicine can simultaneously induce pro-inflammatory macrophages and prevents monocyte differentiation [43]. Thus, it is clear that the contradictory effects of colchicine on inflammation and immune system should be investigated further if we want to utilize a colchicine-immune combinational therapy.…”

Section: Responses Of Monocytes and Macrophages To Microtubule Inhmentioning

confidence: 99%

See 1 more Smart Citation

The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy

Fong

Durkin

Lee

2019

IJMS

View full text Add to dashboard Cite

Cancer immune therapy has recently shown tremendous promise to combat many different cancers. The microtubule is a well-defined and very effective cancer therapeutic target. Interestingly, several lines of evidence now suggest that microtubules are intimately connected to the body’s immune responses. This raises the possibility that the combination of microtubule inhibitors and immune therapy can be a highly effective option for cancer treatments. However, our understanding on this potentially important aspect is still very limited, due in part to the multifaceted nature of microtubule functions. Microtubules are not only involved in maintaining cell morphology, but also a variety of cellular processes, including the movement of secretory vesicles and organelles, intracellular macromolecular assembly, signaling pathways, and cell division. Microtubule inhibitors may be subdivided into two classes: Anti-depolymerization agents such as the taxane family, and anti-polymerization agents such as colchicine and vinka alkaloids. These two different classes may have different effects on immune cell subtypes. Anti-depolymerization agents can not only induce NK cells, but also appear to inhibit T regulatory (Treg) cells. However, different inhibitors may have different functions even among the same class. For example, the doxetaxel anti-depolymerization agent up-regulates cytotoxic T cells, while paclitaxel down-regulates them. Certain anti-polymerization agents such as colchicine appear to down-regulate most immune cell types, while inducing dendritic cell maturation and increasing M1 macrophage population. In contrast, the vinblastine anti-polymerization agent activates many of these cell types, albeit down-regulating Treg cells. In this review, we focus on the various effects of tubulin inhibitors on the activities of the body’s immune system, in the hope of paving the way to develop an effective cancer therapy by combining tubulin-targeting anticancer agents and immune therapy.

show abstract

Section: Responses Of Monocytes and Macrophages To Microtubule Inhmentioning

confidence: 99%

Section: Responses Of Monocytes and Macrophages To Microtubule Inhmentioning

confidence: 99%

The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy

Fong

Durkin

Lee

2019

IJMS

View full text Add to dashboard Cite

show abstract

Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence

Cimmino

Loffredo

Rosa

et al. 2023

IJMS

View full text Add to dashboard Cite

Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Mediterranean fever. To date, current guidelines of the European Society of Cardiology have included colchicine as first line choice for treatment of acute and recurrent pericarditis. Moreover, several studies have investigated its role in the clinical scenarios of cardiovascular disease including chronic and acute coronary syndromes with promising results. In this review, starting from a description of the mechanism(s) involved behind its anti-inflammatory effects, we give an overview on its potential effects in atherothrombosis and finally present an updated overview of clinical evidence on the role of this drug in cardiovascular disease.

show abstract

Pro-Inflammatory Effects of Colchicine on Macrophages Stimulated with Atherogenic Stimuli in Vitro

Cited by 2 publications

References 0 publications

The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy

The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy

Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence

Contact Info

Product

Resources

About